Literature DB >> 16531634

Fluoxetine enhances the anticonvulsant effects of conventional antiepileptic drugs in maximal electroshock seizures in mice.

Kinga K Borowicz1, Karolina Stepień, Stanisław J Czuczwar.   

Abstract

The present study was designed to investigate the effects of fluoxetine (FXT), a selective serotonin reuptake inhibitor, on the effect of antiepileptic drugs (AEDs) in the maximal electroshock seizure (MES) model in mice. FXT at the doses of 25, 20 and 15 mg/kg significantly increased the electroconvulsive threshold. The antidepressant applied at the lower doses (10, 5 and 2.5 mg/kg) did not influence the threshold. Moreover, FXT (at the highest subprotective dose of 10 mg/kg) increased the anticonvulsive potential of carbamazepine (CBZ), diphenylhydantoin (DPH), valproate (VPA) and phenobarbital (PB), producing a dose-related decrease in their ED50 values against MES. Nevertheless, pharmacokinetic events may be involved in the interaction between FXT and PB or CBZ, since the antidepressant raised the total brain concentration of the two antiepileptics. FXT in combination with AEDs did not influence the motor performance in the chimney test and long-term memory. In conclusion, the data suggest that FXT modulates seizure processes in the brain and may be advantageous in the treatment of epilepsy in depressed patients, improving the seizure control in epilepsy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16531634

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  8 in total

1.  Gene-class analysis of expression patterns induced by psychoactive pharmaceutical exposure in fathead minnow (Pimephales promelas) indicates induction of neuronal systems.

Authors:  Michael A Thomas; Parag P Joshi; Rebecca D Klaper
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2011-06-06       Impact factor: 3.228

Review 2.  Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder?

Authors:  L Cardamone; M R Salzberg; T J O'Brien; N C Jones
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

3.  Validation of a Preclinical Drug Screening Platform for Pharmacoresistant Epilepsy.

Authors:  Melissa L Barker-Haliski; Kristina Johnson; Peggy Billingsley; Jennifer Huff; Laura J Handy; Rizvana Khaleel; Zhenmei Lu; Matthew J Mau; Timothy H Pruess; Carlos Rueda; Gerald Saunders; Tristan K Underwood; Fabiola Vanegas; Misty D Smith; Peter J West; Karen S Wilcox
Journal:  Neurochem Res       Date:  2017-03-16       Impact factor: 3.996

4.  Effect of acute and chronic treatment with milnacipran potentiates the anticonvulsant activity of conventional antiepileptic drugs in the maximal electroshock-induced seizures in mice.

Authors:  Kinga K Borowicz; Kamila Furmanek-Karwowska; Marta Morawska; Jarogniew J Luszczki; Stanislaw J Czuczwar
Journal:  Psychopharmacology (Berl)       Date:  2009-10-20       Impact factor: 4.530

5.  Acute and chronic treatment with mianserin differentially affects the anticonvulsant activity of conventional antiepileptic drugs in the mouse maximal electroshock model.

Authors:  Kinga K Borowicz; Monika Banach; Radosław Zarczuk; Dariusz Lukasik; Jarogniew J Luszczki; Stanislaw J Czuczwar
Journal:  Psychopharmacology (Berl)       Date:  2007-07-26       Impact factor: 4.530

Review 6.  Serotonin and sudden unexpected death in epilepsy.

Authors:  Alexandra N Petrucci; Katelyn G Joyal; Benton S Purnell; Gordon F Buchanan
Journal:  Exp Neurol       Date:  2019-12-19       Impact factor: 5.330

7.  Synthesis and Pharmacological Valorization of Derivatives of 4-Phenyl-1,5-Benzodiazepin-2-One.

Authors:  Terence Nguema Ongone; Redouane Achour; Mostafa El Ghoul; Latifa El Ouasif; Khalid Taghzouti; Meryem El Jemli; Yahia Cherrah; Katim Alaoui; Amina Zellou
Journal:  Adv Pharmacol Sci       Date:  2018-04-01

Review 8.  How Antidepressant Drugs Affect the Antielectroshock Action of Antiseizure Drugs in Mice: A Critical Review.

Authors:  Kinga K Borowicz-Reutt
Journal:  Int J Mol Sci       Date:  2021-03-03       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.